Are You Confident of the Diagnosis?
Prototechosis is a rare infectious disease that can be primary cutaneous, subcutaneous, articular (olecranon bursitis) or systemic. Usually protothecosis is not suspected clinically.
What you should be alert for in the history
The history of trauma, surgery, orthopedic procedures, insect bites, or penetration of the agent through skin injury in contact with contaminated water is very common. In most described cases, there is a history of immunosuppression (local or systemic), such as steroid use, malignancy, diabetes mellitus, and organ transplantation.
Characteristic findings on physical examination
The clinical manifestations can sometimes mimic unusual or deep fungal infections. The clinical manifestations may be polymorfic: papules, nodules, eczematous patches, plaques, vesicles, cellulitis, wound infections, tenosynovitis, lymphadenitis, herpetiform lesions, or less commonly, in ulcerative or purulent forms. The cutaneous lesions generally are on exposed sites such as extremities, especially forearms (
(Plaque recovered with pustule. Courtesy of Fabiana Pirani Carneiro, MD, Hospital Universitário de Brasília-UNB).
An infiltrated eczema-like plaque on the right forearm recovered with many pustule-like lesions. (Courtesy of Andrea M Godoy, MD, Santa Casa de Misericordia de São Paulo).
Nail with protothecosis. (Courtesy of Andrea M Godoy, MD, Santa Casa de Misericordia de São Paulo).
Expected results of diagnostic studies
Diagnosis confirmation should be made with the utilization of mycologic tests and pathological evaluation. The histophatologic evaluation of protothecosis is similar to that observed in subcutaneous mycotic lesions. It shows a suppurative and granulomatous infiltration in the dermis or subcutaneous tissue (
H&E staining (courtesy of Fabiana Pirani Carneiro, MD, Hospital Universitário de Brasília-UNB).
Prototheca must be differentiated from some fungal infections. Prototheca appears only with special staining such as periodic acid schiff (PAS), gomori methenamine-silver (GMS) or Griedly fungal staining. PAS is the best special staining that enables the visualization of the cell wall and also the diagnostic internal septations. This algae has a characteristic morula-like sporangia containing multiple endospores (
Pathological examination showing round, colorless structures and typical morula elements with symmetric subdivisions characteristic of Prototheca spp. (HE)- courtesy of Dra Andrea M Godoy - Santa Casa de Misericordia de São Paulo).
P zopfii does not form multiple septate structures. P wickerhamii presents a morula form of sporangia that containing from 2 to 20 autospores symmetrically arranged like a daisy. It is important to know that the sporangia of Coccidioides immitis and Rhinosporidium sp. are larger and contain somewhat smaller endospores and multiple sporangia. The spores have internal septations of a cartwheel-like appearance.
The specific diagnosis of cutaneous protothecosis could be confirmed by culture of skin tissues (
The differential diagnosis includes eczema, subcutaneous mycosis, deep fungal infections, lupus vulgaris, Majjochi's granuloma and pyoderma. These are differentiated by histology and culture results.
Cultures. (Courtesy of Andrea M Godoy, MD, Santa Casa de Misericordia de São Paulo)
Who is at Risk for Developing this Disease?
Protothecosis has been reported to occur associated with immunosuppression states, either local or systemic. Risk factors include underlying malignancy and chemotherapy, diabetes mellitus, organ transplantation, long-term corticosteroid therapy (even topical), surgery, chronic dialysis, AIDS, and other immunocompromised states.
The algae is ubiquitous in nature and has a world-wide distribution. It is found in beef, pork, crabs, plant products, soil and water in tanks, swimming pools, lakes, sewage, slime flux of trees, industrial ponds and tap water. Approximately 100 cases of this human disease were reported over 25 years in USA, Africa, Asia, Brazil, and some European countries.
What is the Cause of the Disease?
Protothecosis is caused by the achlorophyllic algae of the genus Prototheca. This genus consists of multiple species of nonpigmented algae from the family Chorellaceae. These microorganisms are microscopic, unicellular, achlorophyllous, saprophytic and reproduce asexually by endosporulation. Four species are recognized: P wickerhanii, P zopfii, P stagnora and P filamenta. The first species is the principal agent in human cases of infection and P zopfii is also known to infect humans.
The pathogenic mechanisms of the organism remains unclear, but it is believed that they may infect humans by contact with a potential source such as contaminated water and soil, or by traumatic inoculation of the algae, or during surgery or orthopedic procedures.
These organisms are likely of low virulence in patients with an intact immune system. The infection usually spreads indolently in local areas but may be more widespread in immunocompromised hosts. This disease is not thought to be transmitted from person to person. The incubation period is unknown, it has been speculated to be weeks to months.
Systemic Implications and Complications
The course of protothecosis is one of a chronic, low-grade inflammation that may be indolent. There is one case described of an immunocompromised host who developed disseminated cutaneous protothecosis with pulmonary involvement.
Treatment options are summarized in
Treatment options for protothecosis
|Medical treatment||Surgical procedures||Physical modalities|
|Azoles: ketoconazole, itraconazole, fluconazole and miconazole||Surgical procedures of localizated lesions or of olecranon bursitis|
|Amphotericin B + tetracycline|
Optimal Therapeutic Approach for this Disease
Although treatment of protothecosis is a subject of controversy, the literature suggests using treatments with antifungal agents that have an inhibitory action on ergosterol metabolism (the component of the algae cell membrane). Imidazole antifungal agents may be the first choice in limited cutaneous infection in immunocompetent patients. Itraconazole appears to be the most effective agent of this drug class, and should be administered at 200 mg once a day for 2 months. Hepatotoxicity with ketoconazole has been described.
Intravenous administration of amphotericin B has been recommended for disseminated cases or visceral protothecosis occurring in immunosuppressed patients.
Surgical procedures have been recommended for localizated lesions.
A recently study shows the in vitro efficacy of some essential oils to complement protothecosis therapy in animals and human beings.
Patients should be re-evaluated clinically, histologically and or mycologically, some weeks (2-7) after the treatment to be sure of total remission.
Unusual Clinical Scenarios to Consider in Patient Management
There are reports of cutaneous and noncutaneous protothecosis in AIDS patients presenting with meningitis and tenosynovitis.
(Review of the characteristics of protothecosis and a report of the third Brazilian case of the disease.)
(Report of five cases of cutaneous protothecosis and a review of the literature.)
(A review of the literature of protothecosis.)
(A complete review of the principal cutaneous manifestations of protothecosis.)
(Review of the principal characteristics of the cutaneous manifestations of protothecosis.)
(Review of the literature and an excellent case of protothecosis in an immunocompromised patient.)
Copyright © 2017, 2012 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
- Nursing Practice Change Improved Chemo Administration, But Old Habits Die Hard
- Clinical Research Nursing Staff an Important Part of Oncology Clinical Trial Programs
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Multimodal Follow-up Improved Postradiotherapy Sexual Health in Lower GI, Gynecologic Cancers
- Panobinostat vs Placebo: Patient-Reported Outcomes Comparable in Multiple Myeloma
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Hair Dyes and Cancer Risk (Fact Sheet)
- Low Level Laser Therapy May Prevent Oral Mucositis During HSCT Conditioning
- Counseling Intervention That Improved CHD is Applied to Cancer Risk in Men
- Low-fat Diet May Improve Overall Survival in Newly Diagnosed Breast Cancer
- Multiple Treatment Modalities for Brain Metastasis in Patients With EGFR-mutant Non-small Cell Lung Cancer
- IDDS and SCS: Exploring Multimodal Approaches for Managing Cancer Pain
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|